Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30139595 | 1.00 | ERN1 (0.32) | ERN1 | |
| SCHEMBL20938996 | 0.80 | — | — | |
| SCHEMBL2170779 | 0.79 | TRIM24 (0.31) | ERN1 | |
| SCHEMBL1574793 | 0.78 | — | — | |
| SCHEMBL29950643 | 0.77 | ERN1 (0.34) | ERN1 | |
| SCHEMBL23887606 | 0.76 | ERN1 (0.33) | ERN1 | |
| SCHEMBL31337139 | 0.74 | ALDH1A1 (0.32) | — | |
| SCHEMBL22342564 | 0.74 | ALDH1A1 (0.32) | — | |
| SCHEMBL24609032 | 0.74 | RRM2 (0.45) | — | |
| SCHEMBL20268024 | 0.74 | HSD17B10 (0.34) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624036-A | Method for preparing 6-bromo-3-fluoro-2-pyridinecarboxaldehyde | 爱斯特（成都）生物制药股份有限公司 | 2024-03-01 | — | — | CN | claimed |
| EP-3697769-B1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | CENTRE NAT RECH SCIENT (FR) | 2023-02-15 | — | — | EP | claimed |
| US-11370772-B2 | 6-Substituted 3-Fluoro-2-Pyridinaldoxime, 3-Fluoro-2-pyridine hydroxamic acid, and 3-Fluoro-2-Pyridinamidoxime scaffolds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-28 | — | — | US | claimed |
| EP-3697769-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | Centre National De La Recherche Scientifique (FR) | 2020-08-26 | — | — | EP | claimed |
| US-20200255399-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | UNIVERSITÉ DE STRASBOURG (50%) (FR) | 2020-08-13 | — | — | US | claimed |
| WO-2019076986-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-04-25 | — | — | WO | claimed |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4714953-A1 | MELANOCORTIN 2-TYPE RECEPTOR ANTAGONIST | Scohia Pharma, Inc. (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-10-09 | — | — | US | disclosed |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| US-12358907-B2 | Substituted pyrrolidine amides III | Grünenthal GmbH (DE) | 2025-07-15 | — | — | US | disclosed |
| EP-4574822-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2025-06-25 | — | — | EP | disclosed |
| EP-2178876-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | AstraZeneca AB (SE) | 2010-04-28 | — | — | EP | disclosed |
| US-20100048635-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20100048635-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| WO-2009010801-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| WO-2007017146-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358907-B2 | Substituted pyrrolidine amides III | NR3C1, NR3C2, MC2R | ERN1 2681/4885 |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | ERN1 3617/4885 |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | ERN1 1159/4885 |
| US-20200255399-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | PNPO, ACHE, PSEN2 | ERN1 2309/4885 |
| US-20100048635-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | PARK7, HSPA9, NLN | ERN1 2890/4885 |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | PARK7, HSPA9, NLN | ERN1 2890/4885 |
| US-11370772-B2 | 6-Substituted 3-Fluoro-2-Pyridinaldoxime, 3-Fluoro-2-pyridine hydroxamic acid, and 3-Fluoro-2-Pyridinamidoxime scaffolds | PNPO, ACHE, PSEN2 | ERN1 2309/4885 |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | ADORA1, ADORA3, ADORA2A | ERN1 2494/4885 |
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | ERN1 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.